volume (cortical or cancellous), bone turnover, osteoclast number or whole bone mechanical properties. Conclusions: These data indicate that while calcitriol effectively lowered PTH in rats with CKD, it did little to prevent the negative effects of secondary hyperparathyroidism on the skeleton.
Calcitriol, vitamin D analogs and calcimimetics all lower PTH, but data that assess their efficacy on bone are rather limited. While most osteoporosis clinical studies in non-CKD patients demonstrate that calcitriol reduces fracture risk through improvements in BMD [12, 13] , the extension of these benefits to patients with advanced kidney disease where cortical bone is adversely affected is unclear [4] . Preclinical studies using calcium to suppress PTH to normal (or below) levels largely preserves skeletal properties [14] [15] [16] [17] . Unfortunately, this effectiveness comes at the cost of increased vascular calcification, at least when hypercalcemia ensues. These data are consistent with concerns raised in CKD patients about the use of calcium supplementation and calcium-based phosphate binders [18] [19] [20] [21] [22] [23] .
In light of these data, a more thorough examination of the effects of calcitriol therapy on specific skeletal outcomes seems warranted. Despite widespread use clinically, there are limited calcitriol intervention studies in humans and animal models that examine tissue properties (histomorphometry, trabecular architecture, cortical geometry, etc.). Fracture prevention studies have not been conducted for calcitriol in patients with CKD, and limited preclinical studies have evaluated mechanical properties of bone with intervention. The goal of the current study was to fill these voids in a preclinical model of CKD. Specifically, we sought to investigate how suppression of PTH levels with calcitriol would impact skeletal properties using an animal model of progressive CKD.
Methods

Animal Model
Cy/+ rats are characterized by autosomal dominant cystic disease [24] . These animals have a mutation (R823W) in Anks6 , a gene that codes for the protein SamCystin. The exact function of this protein is unknown [25] , but unlike many other cyst-related proteins, SamCystin does not localize to the primary cilia of kidney cells [26] . Recently, this gene was shown to be responsible for nephronophthisis in humans [27] . In this rat model, the mutation leads to a slow and gradual onset of CKD [24] . It parallels the human condition through the progressive development of hyperphosphatemia, secondary hyperparathyroidism and vascular calcification. Blood urea nitrogen (BUN) and creatinine are elevated by 20 weeks of age. Skeletal abnormalities consistent with osteitis fibrosa cystica are present by 30 weeks.
Experimental Design
At 24 weeks, male Cy/+ rats were placed on a casein diet (Purina AIN-76A; 0.7% Pi, 0.6% Ca), which we have shown to produce a more consistent kidney disease phenotype [24] . At this point, these animals have reached their full adult weights. Starting at 25 weeks of age, Cy/+ rats were treated with vehicle (n = 9) or calcitriol (n = 11; 10 ng/kg 3× weekly; intraperitoneal) for 5 weeks.
This treatment duration was chosen as it approximates an average bone remodeling cycle in skeletally mature rats (roughly 6 months in humans) and has been shown to be sufficient to detect treatment-induced skeletal changes in this model [28, 29] . Based on preliminary studies in these animals, calcitriol doses were chosen to achieve approximately 50% suppression of PTH levels. Nonaffected male littermates served as controls (n = 8). All rats were injected with calcein (10 mg/kg; subcutaneous) 14 and 4 days prior to sacrifice to label surfaces with active bone formation.
At 30 weeks of age, animals were anesthetized with isoflurane and underwent cardiac puncture for blood draw followed by exsanguination and bilateral pneumothorax to ensure death. The lumbar spine, tibiae and femora were removed and stored at -20 ° C for analysis. All procedures were approved by and carried out according to the rules and regulations of the Indiana University School of Medicine's Institutional Animal Care and Use Committee. Some of the data from normal and CKD-VEH animals have been published previously as these control groups were part of a larger study of which calcitriol treatment was one sub-group [54] .
Biochemistry
Blood plasma at 30 weeks was analyzed for BUN, calcium and phosphorus using colorimetric assays (Point Scientific, Sigma kits, Canton, M.I., USA). Intact PTH was determined by ELISA (Alpco, Salem, N.H., USA).
MicroCT
Using microCT (Skyscan 1172), trabecular architecture was determined from the metaphysis of the proximal tibia and the full length of the L4 vertebra. Cortical bone geometry was determined from the femoral midshaft. Cortical thickness (Ct.Th) was assessed at 75% of the height of the vertebra (from cranial to caudal) because this represents a region free of zygapophyseal attachment. All bones were wrapped in parafilm to prevent drying and scanned at a resolution of 12 μm in accordance with standard guidelines [30] .
Histomorphometry
Static and dynamic histomorphometric measures were obtained from the proximal metaphysis of the tibia as well as the caudal metaphysis of the L3 vertebra. Histological processing followed previously used protocols from this lab [31] [32] [33] . Tissues were embedded in methyl methacrylate for undecalcified sections. Transverse sections from the proximal tibia and frontal sections from the caudal portion of the L3 vertebra were cut and left unstained for dynamic histomorphometry or stained with tartrate-resistant acid phosphatase (TRAP) for osteoclast measurements (tibia only). For cancellous bone, a region of interest that was approximately 0.8 mm from the growth plate was analyzed. Unstained sections were assessed for total bone surface (BS), single-labeled surface and double-labeled surface to calculate mineral apposition rate (MAR), percent mineralizing surface (MS)/BS and bone formation rate (BFR)/BS. TRAP-stained sections were assessed for BS, osteoclast number and osteoclast surface (Oc.S) to calculate the number of osteoclasts per unit BS and percent Oc.S/BS. All histomorphometric nomenclature follows standard usage [34] .
Whole Bone Mechanics
Structural mechanical properties of femora were determined by 4-point bending. The anterior surface was placed on 2 lower supports located ±9 mm from the mid-diaphysis (18 mm span length) with an upper span length of 6 mm. Specimens were loaded to failure at a rate of 2 mm/min. Structural mechanical properties were obtained directly from the force-displacement curves, while apparent material properties were derived from the forcedisplacement curves, cross-sectional moments of inertia and the distances from the centroid to the tensile surface using standard beam bending equations for 4-point bending [35] .
Structural mechanical properties of L4 vertebrae were determined by uniaxial compression. Vertebra height was assessed from microCT images. Prior to mechanical testing, the vertebral arch and end plates were removed to create parallel surfaces for compression testing. Specimens were loaded at a rate of 0.5 mm/min. Structural mechanical properties were obtained directly from the force-displacement curves, while apparent material properties were derived from the force-displacement curves, pre-test sample heights and the average bone area of 5 microCT slices (10, 30, 50, 70 and 90% slices of the pre-test sample height) using equations for uniaxial compression [36, 37] .
Tissue Composition
The anteromedial portion of the tibial mid-diaphysis was polished with a 0.05 μm alumina suspension in order to create a flat region for spectroscopy and indentation testing. Composition was assessed using a LabRAM HR 800 Raman Spectrometer (HORIBA JobinYvon, Edison, N.J., USA). A 660 nm laser was focused on the BS using a 50X objective to a spot size of ∼ 10 μm. Three locations were imaged ∼ 3 mm apart with 520 s acquisitions at each location as previously published [38] . A 5-point linear baseline correction was applied in LabSpec 5 (HORIBA JobinYvon). Using OriginPro 8.6 (OriginLab, Northampton, Mass., USA), a single Gaussian peak was fit to the PO 4 3-ν1 peak, and the areas under the PO 4 3-ν1, CO 3 2-ν1 and Amide I peaks were calculated at each location. Type B carbonate substitution was found by the band area ratio of CO 3 2-ν1/PO 4 3-ν1. The degree of matrix mineralization was determined by the band area ratio of PO 4 3-ν1/Amide I. Mineral maturity (crystallinity) was determined by the inverse of the full width at half maximum of the PO 4 3-ν1 peak.
Nanoindentation
After Raman spectroscopy, nanoindentation was performed on the same samples using a Hysitron TI 950 TriboIndenter. Samples were partially submerged in ultrapure water with the surface remaining uncovered for optical imaging of the surface to determine indentation locations but then fully submerged during testing. Locations were imaged using in situ scanning probe imaging. Then, 6 indentations were performed on a 10 × 20 μm grid, avoiding interactions from neighboring indentations. A previously calibrated fluid cell Berkovich diamond probe was used for the indentations. Machine calibrations were performed at the beginning of each day of testing. Tests were conducted in load control with a 10 s loading period, a 10 s hold at 3,000 μN and a 10 s unloading period. From the resulting load-displacement profiles, the indentation elastic modulus and hardness were calculated according to the following equations:
where E r is the reduced indentation elastic modulus of the sample, A is contact area, h c is the contact displacement, S is the stiffness of the sample determined from 40 to 95% of the unloading slope, H is the hardness of the sample and P max is the peak force. All of the individual indentations (n = 6 per location) were averaged to produce a single value for each location, and each of these locations was averaged to produce a single value for each sample.
Statistics
Comparisons among groups were assessed by one-way analysis of variance with Fisher's LSD post-hoc tests. A priori α-levels were set at 0.05 to determine significance.
Results
Mineral Metabolism
Animals with CKD had higher serum levels of BUN compared to normal littermates. Serum calcium was normal, while phosphorus and PTH levels were significantly higher than their normal counterparts ( table 1 ) . Animals treated with calcitriol had BUN, calcium and phosphorus values similar to their untreated CKD counterparts. PTH levels in calcitriol animals were significantly lower than in untreated CKD animals (-61%) but still higher than in normal controls (+381%). MicroCT Vehicle-treated CKD animals had lower trabecular bone volume than normal animals at the proximal tibia. A similar pattern was observed in the vertebra. In both cases, animals treated with calcitriol displayed no differences than their CKD vehicle counterparts ( fig. 1 and  table 2 ). All other trabecular parameters were similar between calcitriol animals and the untreated CKD animals.
Cortical bone of the femoral midshaft and lumbar vertebra was also negatively affected by CKD. CKD animals had lower cortical area (Ct.Ar), Ct.Th and bending moments of inertia compared to those of normal controls ( table 2 ) . Animals treated with calcitriol displayed cortical values similar to CKD vehicle animals. Calcitriol did not correct CKD-induced changes in Ct.Ar, thickness, porosity or polar moment of inertia of the femur or Ct.Th of the vertebra ( table 2 ). BV/TV = Bone volume/tissue volume; Tb.Th = trabecular thickness; Tb.N = trabecular number; Tb.Sp = trabecular spacing; I ap = moment of inertia in the anterior-posterior direction; I ml = moment of inertia in the medial lateral direction; Ct.Po = cortical porosity. 
Histology
Vehicle-treated CKD animals had higher trabecular BFRs in the tibia and vertebra as well as higher osteoclast number and percent Oc.S than their normal counterparts ( fig. 2 and table 3 ) . Calcitriol animals displayed similar values to CKD vehicle animals with regard to MAR, osteoclast number and percent Oc.S. While animals with calcitriol had a slightly higher proportion of MS than CKD vehicle animals (in the tibia only), BFRs at both sites were similar between these groups.
Whole Bone Mechanics
Animals with CKD had lower femoral ultimate force, stiffness and energy to fracture compared to normal animals ( fig. 3 and table 4 ) . Estimated material properties revealed a significantly lower modulus of toughness in CKD animals ( fig. 3 ) with no differences in the ultimate stress or elastic modulus ( table 4 ) . Animals treated with calcitriol displayed no treatment effects compared to vehicle-treated CKD. They were similar with regard to ultimate force, stiffness and energy to fracture ( fig. 3 ). Calcitriol treatment also had no effect on estimated material properties ( table 4 ) .
Vertebral compression tests, which assess both trabecular and cortical bone, revealed that CKD animals had lower ultimate force and energy to ultimate force but no differences in stiffness compared to normal animals ( fig. 3 ). Estimated material properties were similar among all 3 groups. As above, vertebrae from calcitriol animals were no different from their untreated CKD counterparts. 
Bone Quality
Compared to normal controls, animals with CKD were found to have no differences in indentation properties. Calcitriol had no effect on these properties either ( table 5 ). Tissue composition assessed by Raman spectroscopy revealed no differences in any of the compositional parameters among the groups either.
Discussion
The goal of this study was to assess the impact of PTH suppression on CKD-induced bone disease. Using calcitriol, the current standard of care in patients with secondary hyperparathyroidism, PTH levels were suppressed by 60% in animals with CKD. Despite this reduction, no skeletal benefits were observed. This is likely in part due to the failure of calcitriol to suppress BFRs and osteoclast formation, both of which remained significantly higher than normal in long bones and vertebrae. These data arise important questions regarding the PTH suppression that is needed to produce skeletal benefits in the setting of CKD and whether PTH is an accurate biomarker of bone remodeling and mechanical properties.
In animal studies using calcitriol and paricalcitol in the 5/6th or 7/8th nephrectomy model, the results on bone have been mixed ( table 6 ) [39] [40] [41] [42] . Even in the presence of PTH suppression, only Jokihaara et al. [39] showed positive bone outcomes. In that study, 8-weekold animals underwent 5/6 nephrectomy and were treated with paricalcitol for 15 weeks. Levels of PTH suppression were similar to those in the current study, and femoral neck BMD and mechanical properties were higher than those in CKD animals and equivalent to those in normal animals. Yet, no beneficial effects were observed in BMD or mechanical properties at the femoral diaphysis (a site assessed in the current study). While variations in these models may explain some of the skeletal differences, one possible explanation is that calcitriol has a preferential effect at certain skeletal sites. Although the femoral neck is a clinically relevant site, why it would be positively affected when the proximal tibia, femoral diaphysis and lumbar vertebra in the current study were not is unclear.
Despite the plethora of data showing the effectiveness of calcitriol and its analogs to suppress PTH in patients with advanced CKD [4, [43] [44] [45] [46] , far fewer clinical studies have examined the impact of these treatments on bone outcomes ( table 7 ) . As reviewed in the KDIGO CKD-MBD guidelines, the evidence supporting a skeletal benefit of calcitriol or its analogs is weak [3] . In pediatric populations, calcitriol therapy has consistently shown effective suppression of bone turnover, though the associated suppression of PTH has been much more variable [47] [48] [49] . Skeletal results in adult populations have been far less congruous. For example, 1 study in dialysis patients revealed increased BMD at the spine and the hip, even though PTH levels were not impacted [50] . Studies have described significant reductions in osteoblast surface/BS and Oc.S/BS in conjunction with a 73% decrease in PTH [51] . Conversely, other studies have shown no difference in these osteoblast/osteoclast parameters associated decrease in PTH [52, 53] , although these studies were not designed to specifically study suppression of PTH to a given level. Despite some studies documenting changes in osteoblast and Oc.S measures, no study has documented differences/changes in the dynamic measures provided by fluorescent labeling, further adding to the obscurity. In summary, pediatric populations appear to be responsive to calcitriol and its analogs as they exhibit PTH suppression with associated changes in dynamic histology parameters. In adults, however, PTH changes are much less consistent, and the only histological changes observed are limited static parameters. These studies demonstrate the need for a fracture prevention clinical trial with calcitriol or its analogs. In the current study, dynamic measures were consistent with the human studies, though osteoclast number and percent surface remained at the level of untreated CKD animals. Most importantly, this study showed that calcitriol had no impact on any whole bone mechanical parameters or on those assessing bone quality. Unfortunately, none of these previous studies revealed clear relationships between bone remodeling and PTH suppression. In contrast, by using calcium in the same animal model, we did demonstrate efficacy in improving bone histology and CT [29] . However, it is unclear if this was a result of increased calcium or more aggressive suppression of PTH. Unfortunately, this approach also led to an exacerbation of arterial calcification. Taken together, these data lend support to previous suggestions that calcitriol may have a direct effect on bone independent of its effect on PTH [46] . Furthermore, because there have been no fracture trials using calcitriol in CKD, the extension of its positive effects in patients with osteoporosis [12, 13] is simply unknown. The future of calcitriol therapy in patients with CKD requires fracture assessments for further evaluation. This raises the question of the goal of treatment with calcitriol and its analogs.
Our study has some limitations. We do not have baseline biochemistries or bone assessments. Previous work in this model shows that at 25 weeks, when we initiated treatment in the current study, the biochemistries are roughly comparable with respect to calcium and phosphorus, while BUN and PTH are already higher in Cy/+ compared to normals [16, 55] . We have not extensively studied the bone phenotype at 25 weeks of age. At 20 weeks of age, Cy/+ animals already have higher osteoblast and Oc.S [55] without significant alterations in bone mass/geometry or mechanical properties. The current experiment was also limited in that only a single dose of calcitriol and a single duration of treatment were studied; it is possible that the outcomes would have differed with modification of either of these variables. Although we achieved our target goal of suppressing PTH by ∼ 50%, which matches the clinical goal of treatment with calcitriol, the levels of PTH in our model (12X normal) far exceed those of humans. Most clinical studies have excluded patients with very high PTH levels and thus it is possible that the degree of hyperparathyroidism or the severity of hyperphosphatemia could influence the efficacy of calcitriol on bone.
The current study demonstrated that calcitriol treatment, while efficacious in terms of PTH suppression in animals with CKD, did little to curb the detrimental effects of secondary hyperparathyroidism from CKD on the skeleton. This was demonstrated by its lack of effect on biochemical, histomorphometric and, most importantly, of all mechanical measures. Taken together, this indicates that a greater degree of PTH suppression may be required for efficacy in skeletal properties to occur in the setting of CKD. Alternatively, there may not be efficacy of calcitriol or its analogs on the skeleton. Fracture studies are greatly needed in this patient population.
